Pharmacoeconomic analysis of the treatment of multiple actinic keratoses.

摘要: Actinic keratosis (AK) is common and lesions may progress to squamous cell carcinoma. The choice of therapy depends mainly on 2 factors: the efficacy therapeutic options number present. Cryotherapy alone suitable for treating a few lesions, whereas topical medications, photodynamic (PDT) with 5-aminolevulinic acid (ALA), or either in combination cryotherapy are appropriate multiple (>15) lesions. When combinations necessary, total cost treat AKs 100% clearance becomes important. This report provides simple pharmacoeconomic analysis 4 FDA-cleared therapies (imiquimod, diclofenac, 5-fluorouacil [5-FU], ALA PDT) AK given cryotherapy. assumes standard costs procedures office visits (based April 2007 reimbursement data) treatment courses (medications: imiquimod, 5-FU) sessions (ALA each modality followed by clearance. $725.17 PDT, $845.07 $942.13 5-FU, $1,473.39 imiquimod. phase III trial efficacies modalities considered, actual using imiquimod diclofenac increases because additional treatments be required. Among these PDT least expensive most under stated assumptions.